Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy von Ihle, Nathan T, Powis, Garth

Volltext

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome von Ihle, Nathan T., Byers, Lauren A., Kim, Edward S., Saintigny, Pierre, Lee, J. Jack, Blumenschein, George R., Tsao, Anne, Liu, Suyu, Larsen, Jill E., Wang, Jing, Diao, Lixia, Coombes, Kevin R., Chen, Lu, Zhang, Shuxing, Abdelmelek, Mena F., Tang, Ximing, Papadimitrakopoulou, Vassiliki, Minna, John D., Lippman, Scott M., Hong, Waun K., Herbst, Roy S., Wistuba, Ignacio I., Heymach, John V., Powis, Garth

Volltext

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance von IHLE, Nathan T, LEMOS, Robert, WIPF, Peter, YACOUB, Adly, MITCHELL, Clint, SIWAK, Doris, MILLS, Gordon B, DENT, Paul, KIRKPATRICK, D. Lynn, POWIS, Garth

Volltext

An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors von Indarte, Martin, Puentes, Roisin, Maruggi, Marco, Ihle, Nathan T, Grandjean, Geoffrey, Scott, Michael, Ahmed, Zamal, Meuillet, Emmanuelle J, Zang, Shuxing, Lemos, Jr, Robert, Du-Cuny, Lei, Layng, Fabiana I A L, Correa, Ricardo G, Bankston, Laurie A, Liddington, Robert C, Kirkpatrick, Lynn, Powis, Garth

Volltext

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy von Ihle, Nathan T., Powis, Garth

Volltext

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling von Ihle, Nathan T, Williams, Ryan, Chow, Sherry, Chew, Wade, Berggren, Margareta I, Paine-Murrieta, Gillian, Minion, Daniel J, Halter, Robert J, Wipf, Peter, Abraham, Robert, Kirkpatrick, Lynn, Powis, Garth

Volltext

Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine von Zhu, Zhou, Ihle, Nathan T, Rejto, Paul A, Zarrinkar, Patrick P

Volltext

Stability of Phosphoprotein as a Biological Marker of Tumor Signaling von BAKER, Amanda F, DRAGOVICH, Tomislav, IHLE, Nathan T, WILLIAMS, Ryan, FENOGLIO-PREISER, Cecilia, POWIS, Garth

Volltext

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenogr... von Ihle, Nathan T, Paine-Murrieta, Gillian, Berggren, Margareta I, Baker, Amanda, Tate, Wendy R, Wipf, Peter, Abraham, Robert T, Kirkpatrick, D Lynn, Powis, Garth

Volltext

Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer von Bar-Peled, Liron, Kemper, Esther K., Suciu, Radu M., Vinogradova, Ekaterina V., Backus, Keriann M., Horning, Benjamin D., Paul, Thomas A., Ichu, Taka-Aki, Svensson, Robert U., Olucha, Jose, Chang, Max W., Kok, Bernard P., Zhu, Zhou, Ihle, Nathan T., Dix, Melissa M., Jiang, Ping, Hayward, Matthew M., Saez, Enrique, Shaw, Reuben J., Cravatt, Benjamin F.

Volltext

The Pten-Parkin Axis: At the Nexus of Cancer and Neurodegeneration von Ihle, Nathan T., Abraham, Robert T.

Volltext

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting... von Ihle, Nathan T, Lemos, Robert, Schwartz, David, Oh, Junghwan, Halter, Robert J, Wipf, Peter, Kirkpatrick, Lynn, Powis, Garth

Volltext

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer von Lee, Catherine, Jiang, Ziyue Karen, Planken, Simon, Manzuk, Lisa K, Ortiz, Roberto, Hall, Michael, Noorbehesht, Kavon, Ram, Sripad, Affolter, Timothy, Troche, Gabriel E, Ihle, Nathan T, Johnson, Theodore, Ahn, Youngwook, Kraus, Manfred, Giddabasappa, Anand

Volltext

Correction: An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors von Indarte, Martin, Puentes, Roisin, Maruggi, Marco, Ihle, Nathan T, Grandjean, Geoffrey, Scott, Michael, Ahmed, Zamal, Meuillet, Emmanuelle J, Zhang, Shuxing, Lemos, Jr, Robert, Du-Cuny, Lei, Layng, Fabiana I A L, Correa, Ricardo G, Bankston, Laurie A, Liddington, Robert C, Kirkpatrick, Lynn, Powis, Garth

Volltext

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling von WILLIAMS, Ryan, BAKER, Amanda F, IHLE, Nathan T, WINKLER, Ashley R, KIRKPATRICK, Lynn, POWIS, Garth

Volltext

Inhibiting PI-3-K for glioma therapy von Powis, Garth, Ihle, Nathan T., Yung, W.K. Alfred

Volltext

Take your PIK: PI-3-kinase inhibitors race through the clinic and towards cancer therapy von Ihle, Nathan T., Powis, Garth

Volltext

Abstract 1842: PHT-782 an inhibitor of the KRAS signaling nanocluster protein CNKSR1 blocks mutant KRAS signaling and cell growth but does not inhibit wild type KRAS cell growth von Ihle, Nathan T., Zhang, Shuxing, Indarte, Martin, Kirkpatrick, Lynn, Powis, Garth

Volltext

Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling von Ihle, Nathan T., Grandjean, Geoff, Kingston, John, Zhang, Shuxing, Du-Curry, Lei, Indarte, Martin, Kirkpatrick, Lynn, Powis, Garth

Volltext

Abstract 3454: Establishing role of KRAS mutation on NSCLC radio-sensitivity von Bhardwaj, Vikas, Likhacheva, Anna, Byers, Lauren A. Byers A., Diao, Lixia, Allen, Pamela K., Minna, John D., Ihle, Nathan T., Powis, Garth, Das, Amit K., Girard, Luc, Peyton, Michael, Yordy, John, Liao, Zhongxing, Ang, Kian K., Story, Michael, Kalhor, Neda, Komaki, Ritsuko, Kim, Edward S., Heymach, John V., Welsh, James

Volltext